Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSP 301 NS in Seasonal Allergic Rhinitis
NCT02631551Phase 3Completed
- Sponsor
- Glenmark Specialty
- Start
- Mar 2016
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mometasone in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Glenmark Specialty. Primary endpoint: Reflective Total Nasal Symptom Score at 14 days. Started Mar 2016; status: completed.
02
Drugs
mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02631551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631551.